Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Wells Fargo & Company

organization80% conf.·synced Aug 13, 2026

Major US banking and financial services company

56
sourced metrics
181
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Eps
7.91USD_per_share
May 12, 2026source
Margin
13.27percent
May 12, 2026source
Stock Price
75.64USD
May 12, 2026source
Eps Estimate Fy2026
6.72USD
Apr 15, 2026source
Eps Estimate Fy2027
7.36USD
Apr 15, 2026source
Price Target
108USD
Apr 15, 2026source
Ytd Stock Performance
-13percent
Apr 15, 2026source
Net Interest Income
12.10USD
Apr 15, 2026source
Net Interest Margin Change
-13basis_points
Apr 14, 2026source
Mortgage Banking Revenues
283USD
Apr 14, 2026source
Investment Advisory Fee Growth
12.8percent
Apr 14, 2026source
Net Interest Income Growth
6.9percent
Apr 14, 2026source
Investment Advisory Fees
2.9USD
Apr 14, 2026source
Tax Benefit
135USD
Apr 1, 2026source
Noninterest Income Yoy Growth
8percent
Apr 1, 2026source
Share Repurchases
4USD
Apr 1, 2026source
Tax Benefit Per Share
0.04USD
Apr 1, 2026source
Deposit Growth
7percent
Apr 1, 2026source

Stated objectives

S&P 500 to reach 7,400-7,600 in 2026

source
target: 7400-7600 by 2026-12-31 00:00:00stated

Expected revenue of $21.69 billion for Q1 2026

source
target: 21.69 billion by 2026-04-14 00:00:00stated

Expected full year EPS of $6.91 for FY 2026

source
target: 6.91 by 2026-12-31 00:00:00stated

Expected full year revenue of $88.19 billion for FY 2026

source
target: 88.19 billion by 2026-12-31 00:00:00stated

Maintain CET1 ratio in target range of approximately 10% to 10.5%

source
target: 10-10.5% stated

Achieve total net interest income of approximately $50 billion in 2026

source
target: 50 billion USD by 2026-01-01 00:00:00stated

Achieve Markets NII of approximately $2 billion in 2026

source
target: 2 billion USD by 2026-01-01 00:00:00stated

Achieve NII excluding markets of approximately $48 billion in 2026

source
target: 48 billion USD by 2026-01-01 00:00:00stated

Limit 2026 non-interest expense to approximately $55.7 billion

source
target: 55.7 billion USD by 2026-01-01 00:00:00stated

Achieve approximately $2.4 billion of gross expense reductions in 2026 from efficiency initiatives

source
target: 2.4 billion USD by 2026-01-01 00:00:00stated

Relationship graph · 181 connections

Covered by
64
Competes with
25
Employs
20
regulates
13
acquired by
9
acquired from
9
rates
7
subsidiary of
6
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com